ESALY - European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab | Benzinga
Biogen Inc (NASDAQ:BIIB) and Eisai Co Ltd (OTC:ESALF) (OTC:ESALY) faced a setback as the much-anticipated Oral Explanation slated for March 19 at the Committee for Medicinal Products for Human Use (CHMP) was postponed.
This delay, attributed to procedural issues at the European Medicines Agency (EMA), has implications for the review process of lecanemab, a pivotal drug currently under EMA evaluation.
Also Read: Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall ...